A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.

@article{Niesen2016ANF,
  title={A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.},
  author={Judith Niesen and Grit Hehmann-Titt and Mira Woitok and Rolf Fendel and Stefan Barth and Reinhard Fischer and Christoph W. Stein},
  journal={Cancer letters},
  year={2016},
  volume={374 2},
  pages={
          229-40
        }
}
Human cytolytic fusion proteins (hCFPs) offer a promising immunotherapeutic approach for the treatment of solid tumors, avoiding the immunogenicity and undesirable side-effects caused by immunotoxins derived from plants or bacteria. The well-characterized human serine protease granzyme B has already been used as a therapeutic pro-apoptotic effector domain. We therefore developed a novel recombinant hCFP (GbR201K-scFv1711) consisting of an epidermal growth factor receptor-specific human antibody… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13–ETA′ and the bispecific scFv [13xds16]

  • Journal of Cancer Research and Clinical Oncology
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 78 REFERENCES

G

M. Gehrmann, B. T. Doss, M. Wagner, K. A. Zettlitz, R. E. Kontermann
  • Foulds, et al., A novel expression and purification system for the production of enzymatic and biologically active human granzyme B, J. Immunol. Methods 371
  • 2011
VIEW 21 EXCERPTS
HIGHLY INFLUENTIAL

S

S. Gattenlohner, H. Jorissen, M. Huhn, A. Vincent, D. Beeson
  • Tzartos, et al., A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model, J. Biomed. Biotechnol. 2010 (2010) 187621. 240 J. Niesen et al./Cancer Letters 374
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

K

M. Marcet-Palacios, C. Ewen, E. Pittman, B. Duggan
  • Carmine-Simmen, R.P. Fahlman, et al., Design and characterization of a novel human granzyme B inhibitor, Protein Eng. Des. Sel. 28
  • 2015
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

R

S. Schiffer, D. Hristodorov, R. Mladenov, E. Aslanian, M. Huhn
  • Fischer, et al., Species-dependent functionality of the human cytolytic fusion proteins granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages, Antibodies 2
  • 2013
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL